Immunoprevention of Cancer

Hematology/Oncology Clinics of North America

Volumn 20, Issue 3, 2006, Pages 735-750

  Spisek, Radek ^a   Dhodapkar, Madhav V ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CANCER; CANCER PREVENTION; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOPROPHYLAXIS; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

ANIMALS; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; NEOPLASMS;

EID: 33744522584     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.02.009     Document Type: Review

References (85)

1. Ada G. Vaccines and vaccination. N Engl J Med 345 (2001) 1042-1053
2. Ada G.L. The immunological principles of vaccination. Lancet 335 (1990) 523-526
3. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 4 (2004) 401-411
4. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res 13 (1970) 1-27
5. Stutman O. Immunodepression and malignancy. Adv Cancer Res 22 (1975) 261-422
6. Klein G. Immunological surveillance against neoplasia. Harvey Lect 69 (1973) 71-102
7. Shinkai Y., Rathbun G., Lam K.P., et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68 (1992) 855-867
8. Shankaran V., Ikeda H., Bruce A.T., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
9. Smyth M.J., Crowe N.Y., and Godfrey D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13 (2001) 459-463
10. Street S.E., Cretney E., and Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97 (2001) 192-197
11. Smyth M.J., Thia K.Y., Street S.E., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191 (2000) 661-668
12. Kaplan D.H., Shankaran V., Dighe A.S., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95 (1998) 7556-7561
13. Dighe A.S., Richards E., Old L.J., et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1 (1994) 447-456
14. Bach E.A., Aguet M., and Schreiber R.D. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15 (1997) 563-591
15. Hayakawa Y., Takeda K., Yagita H., et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 100 (2002) 1728-1733
16. Wong L.H., Krauer K.G., Hatzinisiriou I., et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components. STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 272 (1997) 28779-28785
17. van den Broek M.E., Kagi D., Ossendorp F., et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 184 (1996) 1781-1790
18. Dunn G.P., Bruce A.T., Ikeda H., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991-998
19. Street S.E., Trapani J.A., MacGregor D., et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 196 (2002) 129-134
20. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004) 329-360
21. Willimsky G., and Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005) 141-146
22. Pardoll D.M. Cancer vaccines. Nat Med 4 (1998) 525-531
23. Sotomayor E.M., Borrello I., and Levitsky H.I. Tolerance and cancer: a critical issue in tumor immunology. Crit Rev Oncog 7 (1996) 433-456
24. Staveley-O'Carroll K., Sotomayor E., Montgomery J., et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 95 (1998) 1178-1183
25. Marincola F.M., Jaffee E.M., Hicklin D.J., et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74 (2000) 181-273
26. Hung K., Hayashi R., Lafond-Walker A., et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188 (1998) 2357-2368
27. Mumberg D., Monach P.A., Wanderling S., et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 96 (1999) 8633-8638
28. Liotta L.A., and Kohn E.C. The microenvironment of the tumour-host interface. Nature 411 (2001) 375-379
29. Nair S., Boczkowski D., Moeller B., et al. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102 (2003) 964-971
30. Li Y., Wang M.N., Li H., et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 195 (2002) 1575-1584
31. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
32. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
33. Simmons W.J., Simms M., Chiarle R., et al. Induction of germinal centers by MMTV encoded superantigen on B cells. Dev Immunol 8 (2001) 201-211
34. Sen N., Simmons W.J., Thomas R.M., et al. META-controlled env-initiated transcripts encoding superantigens of murine Mtv29 and Mtv7 and their possible role in B cell lymphomagenesis. J Immunol 166 (2001) 5422-5429
35. Hussain S.P., Hofseth L.J., and Harris C.C. Radical causes of cancer. Nat Rev Cancer 3 (2003) 276-285
36. Green J.E., and Hudson T. The promise of genetically engineered mice for cancer prevention studies. Nat Rev Cancer 5 (2005) 184-198
37. Finn O.J., and Forni G. Prophylactic cancer vaccines. Curr Opin Immunol 14 (2002) 172-177
38. Harada N., Tamai Y., Ishikawa T., et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 18 (1999) 5931-5942
39. Reitmair A.H., Redston M., Cai J.C., et al. Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice. Cancer Res 56 (1996) 3842-3849
40. Kuraguchi M., Yang K., Wong E., et al. The distinct spectra of tumor-associated Apc mutations in mismatch repair-deficient Apc1638N mice define the roles of MSH3 and MSH6 in DNA repair and intestinal tumorigenesis. Cancer Res 61 (2001) 7934-7942
41. Hingorani S.R., Petricoin E.F., Maitra A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 (2003) 437-450
42. Guy C.T., Webster M.A., Schaller M., et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89 (1992) 10578-10582
43. Rovero S., Amici A., Carlo E.D., et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165 (2000) 5133-5142
44. Rovero S., Boggio K., Carlo E.D., et al. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. Gene Ther 8 (2001) 447-452
45. Calogero R.A., Musiani P., Forni G., et al. Towards a long-lasting immune prevention of HER2 mammary carcinomas: directions from transgenic mice. Cell Cycle 3 (2004) 704-706
46. Quaglino E., Iezzi M., Mastini C., et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 64 (2004) 2858-2864
47. Quaglino E., Rolla S., Iezzi M., et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 113 (2004) 709-717
48. Spadaro M., Lanzardo S., Curcio C., et al. Immunological inhibition of carcinogenesis. Cancer Immunol Immunother 53 (2004) 204-216
49. Boggio K., Di Carlo E., Rovero S., et al. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 60 (2000) 359-364
50. Nanni P., Nicoletti G., De Giovanni C., et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 194 (2001) 1195-1205
51. Di Carlo E., Rovero S., Boggio K., et al. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clin Cancer Res 7 (2001) 830s-837s
52. Iinuma T., Homma S., Noda T., et al. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J Clin Invest 113 (2004) 1307-1317
53. Gendler S.J., and Mukherjee P. Spontaneous adenocarcinoma mouse models for immunotherapy. Trends Mol Med 7 (2001) 471-475
54. Mukherjee P., Ginardi A.R., Madsen C.S., et al. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J 18 (2001) 931-942
55. Mukherjee P., Ginardi A.R., Tinder T.L., et al. MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo. Clin Cancer Res 7 (2001) 848s-855s
56. Dhodapkar M.V. Harnessing host immune responses to preneoplasia: promise and challenges. Cancer Immunol Immunother 54 (2005) 409-413
57. Bartkova J., Horejsi Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
58. Kyle R.A., and Rajkumar S.V. Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin N Am 13 (1999) 1181-1202
59. Dhodapkar M.V., Krasovsky J., Osman K., et al. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 198 (2003) 1753-1757
60. Dhodapkar M.V., Krasovsky J., and Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci U S A 99 (2002) 13009-13013
61. Finn O.J. Premalignant lesions as targets for cancer vaccines. J Exp Med 198 (2003) 1623-1626
62. Boon T., Cerottini J.C., Van den Eynde B., et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12 (1994) 337-365
63. Jager D., Taverna C., Zippelius A., et al. Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol Immunother 53 (2004) 144-147
64. Khong H.T., and Rosenberg S.A. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Res 62 (2002) 3020-3023
65. Kao H., Marto J.A., Hoffmann T.K., et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 194 (2001) 1313-1323
66. Suzuki H., Graziano D.F., McKolanis J., et al. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 11 (2005) 1521-1526
67. Finn O.J. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3 (2003) 630-641
68. Barnd D.L., Lan M.S., Metzgar R.S., et al. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A 86 (1989) 7159-7163
69. Hruban R.H., Adsay N.V., Albores-Saavedra J., et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25 (2001) 579-586
70. Turner M.S., McKolanis J.R., Ramanathan R.K., et al. Mucins in gastrointestinal cancers. Cancer Chemother Biol Response Modif 21 (2003) 259-274
71. Kotera Y., Fontenot J.D., Pecher G., et al. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54 (1994) 2856-2860
72. Pawelec G., Zeuthen J., and Kiessling R. Escape from host-antitumor immunity. Crit Rev Oncog 8 (1997) 111-141
73. Pawelec G., Heinzel S., Kiessling R., et al. Escape mechanisms in tumor immunity: a year 2000 update. Crit Rev Oncol 11 (2000) 97-133
74. Sun J.C., and Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300 (2003) 339-342
75. Janssen E.M., Lemmens E.E., Wolfe T., et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421 (2003) 852-856
76. Qin Z., and Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12 (2000) 677-686
77. Hock H., Dorsch M., Diamantstein T., et al. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 174 (1991) 1291-1298
78. Greenberg P.D., Klarnet J.P., Kern D.E., et al. Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. Prog Exp Tumor Res 32 (1988) 104-127
79. Sasco A.J. World burden of tobacco-related cancer. Lancet 338 (1991) 123-124
80. Viviani S., Jack A., Hall A.J., et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 17 (1999) 2946-2950
81. Bosch F.X., Lorincz A., Munoz N., et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 (2002) 244-265
82. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
83. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
84. Schiffman M., and Castle P.E. The promise of global cervical-cancer prevention. N Engl J Med 353 (2005) 2101-2104
85. Koutsky L.A., Ault K.A., Wheeler C.M., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651